J.P. Morgan Reiterates Neutral Rating on ChemoCentryx Following Analyst Day
May 17, 2013 at 11:37 AM EDT
In a report published Friday, J.P. Morgan analyst Geoff Meacham reiterated a Neutral rating on ChemoCentryx (NASDAQ: CCXI ). In the report, Meacham noted, “The company reviewed the chemokine pathway, scientific rationale for lead programs (Vercirnon in Crohn's disease and CCX140 in diabetic nephropathy), prior data for these programs, and
